CLASS ACTION UPDATE for RMO, CS and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Back to Newsroom
Mentioned in this Article

CLASS ACTION UPDATE for RMO, CS and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Wednesday, May 5, 2021 12:10 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

RMO Shareholders Click Here: https://www.zlk.com/pslra-1/romeo-power-inc-loss-submission-form?prid=15502&wire=1
CS Shareholders Click Here: https://www.zlk.com/pslra-1/credit-suisse-group-ag-loss-submission-form?prid=15502&wire=1
ACAD Shareholders Click Here: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15502&wire=1

* ADDITIONAL INFORMATION BELOW *

Romeo Power, Inc. (NYSE:RMO)

RMO Lawsuit on behalf of: investors who purchased October 5, 2020 - March 30, 2021
Lead Plaintiff Deadline: June 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/romeo-power-inc-loss-submission-form?prid=15502&wire=1

According to the filed complaint, during the class period, Romeo Power, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Romeo had only two battery cell suppliers, not four, (ii) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and business prospects, (iii) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (iv) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (v) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. Given the supply constraint that Romeo was experiencing during the Class Period, Defendants had no reasonable basis to represent that the Company had the ability to meet customer demand and that it would support growth in revenue in 2021.

Credit Suisse Group AG (NYSE:CS)

CS Lawsuit on behalf of: investors who purchased October 29, 2020 - March 31, 2021
Lead Plaintiff Deadline: June 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/credit-suisse-group-ag-loss-submission-form?prid=15502&wire=1

According to the filed complaint, during the class period, Credit Suisse Group AG made materially false and/or misleading statements and/or failed to disclose that: defendants concealed material defects in the Company's risk policies and procedures and compliance oversight functions and efforts to allow high-risk clients to take on excessive leverage, including Greensill Capital ("Greensill") and Archegos Capital Management ("Archegos"), exposing the Company to billions of dollars in losses.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

ACAD Lawsuit on behalf of: investors who purchased June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline : June 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15502&wire=1

According to the filed complaint, during the class period, Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions